Consolidated Financial Results (Tanshin)for the Three Months Ended June 30, 2024 (Based on IFRS)
August 14, 2024
Name of the listed company :CYBERDYNE, INC.
Stock code
:7779
Representative (title):President and CEO
Contact (title):Director and COO
the scheduled date for release of three-month report
Additional materials for the financial results
Information meeting for the financial results

Stock exchange listing
URL
Name
Name
:August 14, 2024
:None
:None

:Growth Section of TSE:https://www.cyberdyne.jp/english:Yoshiyuki Sankai:Shinji Honda
Tel. +81-29-869-9981
Scheduled start of dividend payment:－(Millions of yen: Rounded to the nearest one million yen)
Ⅰ. Consolidated financial results for the three months ended June 30, 2024 (April 1, 2024-June 30, 2024)

1. Consolidated result of operations(percentages denote year-on-year change)
Operating profit(loss)

Revenue%

Profit (loss) attributable toowners of parent%%

Profit (loss) before tax%

Apr.1-June 30, 2024

1,155

10.5

(154)

－

△7

－

Apr.1-June 30, 2023

1,045

39.1

(308)

－

767

106.2

Apr.1-June 30, 2024

Basic earnings (loss)
per share
Yen
0.05

Diluted earnings (loss)
per shareYen
0.05

Apr.1-June 30, 2023

1.56

1.56

11 △96.6330

36.9

2. Consolidated financial position
Total assets
Millions of yen

The ratio of equity
Total equity attributable toattributable to owners ofowners of the parent
the parent to total assets
Millions of yen
Millions of yen%

Total equity

As of June 30, 2024

50,11540,62840,948

81.7

As of March 31, 2024

49,99940,47740,752

81.5

Ⅱ. Dividends

End of
1st quarter(June.30)
Yen

Dividend payments for each term and the year
End of
End ofFiscal year-end
2nd quarter3rd quarter(March.31)(September.30)(December.31)
Yen
Yen
Yen

Fiscal year ended
0.00－
March 31, 2024
Fiscal year ending－
March 31, 2025
Notes:(ⅰ) Changes from the latest released dividend forecasts: none

－

0.00

Total
Yen
0.00

(ⅱ) The table of “Dividends” indicates dividend payments on Common Shares. Dividends on Class Shares (non-listed) for which thenumber of share units differs from Common Shares are shown below as “Dividends on Class Shares”.

Ⅲ. Forecast of consolidated financial results for the fiscal year ending March 31, 2025 (April 1, 2024-March 31, 2025)

As the business of CYBERDYNE Inc. and its group companies (collectively referred to as the “Group”) is based on a new market
with innovative technologies, there are many uncertain factors that could have an impact on its performance and make it difficult
for CYBERDYNE Inc. (the "Company") to provide a forecast with accurate figures. As such the Company will not announce theforecast of consolidated financial results.
Notes:
1. Changes in key subsidiaries during the consolidated three-month period (changes in specific subsidiaries resulting inchanges of consolidation scope): none
new: － (company name: － ) ,excluded: － (company name: － )2. Changes in accounting policies, accounting estimates, and restatement of error corrections(ⅰ) Changes in accounting policies required by IFRS : none(ⅱ) Changes in accounting policies due to reasons other than (ⅰ) : none(ⅲ) Changes in accounting estimates: none
3. Total number of issued shares (Common Shares)(ⅰ) Total number of issued shares at the end of each period (including treasury shares)
As of June 30, 2024

215,145,809 shares

As of March 31, 2024

215,145,809 shares

As of March 31, 2024

4,014,574 shares(ⅱ) Total number of treasury shares at the end of each period
As of June 30, 2024

4,014,574 shares(ⅲ) Average number of shares during each three-month period
Apr.1-June 30, 2024
211,131,235 shares
Apr.1-June 30, 2023
211,131,236 shares
Note: Class B Shares are ranked the same as Common Shares and are paid the same amount as Common Sharesconcerning dividends of surplus and distribution of residual assets. Therefore, the total number of issued sharesat each end of the period and the average number of shares during each period include Class B Shares as
Common Shares.

*This quarterly consolidated financial report is not subject to the quarterly review procedure by the scope of audit.

Dividends on Class Shares
Details of dividends on the Company’s B Class Shares for which the number of share units differs from its Common Shares are as
follows.
End of
1st quarter(June.30)
Yen

Dividend payments for each term and the year
End of
End ofFiscal year end
2nd quarter3rd quarter(March.31)(September.30)(December.31)
Yen
Yen
Yen

Total

Fiscal year ended
0.00
0.00
－
－
March 31, 2024
Fiscal year ending－
March 31, 2025
Note:
The Company issued Class B Shares, which were accorded the same rights as its Common Shares concerning dividends anddistribution of residual assets, but for which share units differ from Common Shares.

Yen
0.00

○ Contents of the Attached Material
1. Qualitative information regarding the settlement of accounts for the three months……………………………………………

2(1) Explanation of operating results.……………………………………………………………………………………………

2(2) Explanation of financial position……………………………………………………………………………………………

5(3) Status of cash flow..…………………………………………………………………………………………………………

6

2. Condensed quarterly consolidated financial statement (Unaudited)……………………………………………………………

7(1) Condensed quarterly consolidated statement of financial position (Unaudited)……………………………………………

7(2) Condensed quarterly consolidated statement of profit or loss and condensed quarterly consolidated statement ofcomprehensive income (Unaudited) ...………………………………………………………………………………………

9

Condensed year to quarter end consolidated statement of profit or loss……………………………………………………

9

Condensed year to quarter end consolidated statement of comprehensive income...………………………………………

10(3) Condensed quarterly consolidated statement of changes in equity (Unaudited)……………………………………………

11(4) Condensed quarterly consolidated statement of cash flows (Unaudited)...…………………………………………………

13(5) Notes to condensed quarterly consolidated financial statements……………………………………………………………

14(Notes on the premise of going concern) …………………………………………………………………………………… 14(Segment information) .……………………………………………………………………………………………………

14(Revenue) ..…………………………………………………………………………………………………………………

15

- 1 -

1. Qualitative information regarding the settlement of accounts for the three months ended June 30, 2024
(1) Explanation of operating result
All forward-looking statements included in this explanation were determined reasonable by CYBERDYNE
Inc. (the “Company”) and its group companies (collectively referred to as the “Group”) based on currently

available information for the consolidated March 31, 2024, and certain assumptions made by the Group.
To solve various issues facing society, the Group will make full use of “Cybernics” (a new field that integrates
and combines human, robot, AI, and information systems) and handle HCPS (Human-Cyber-Physical Space)in a unified manner. Furthermore, through Cybernics, the Group promotes the realization of “Techno Peer
Support” and future development by creating the “Cybernics Industry,” a new industry that will follow the

robotics and IT industries.
The Group defines “Techno Peer Support Society” as a safe and secure society where people and technology
coexist, cooperate and mutually support each other to enhance the independence and freedom of people of all
generations and solve various problems in their lives both mentally and physically. To realize Techno Peer
Support Society and Cybernics Industry, the Group is developing various Cybernics Technologies that
improve, regenerate, expand, and support the wearer’s physical functions.

Status of business operation<<Business operation around the medical application>>
The Group continues its efforts to disseminate Cybernics Treatment, a treatment program using Medical HAL
systems that aims to induce improvement and regeneration of the functions of the brain, nerves, and muscles
into a global standard of treatment.
(Japan)The Group continues its efforts to disseminate Cybernics Treatment, a treatment program using Medical HAL.
Post-marketing surveillance on the Medical HAL Lower Limb Type Double-leg Model suggested a highefficacy and safety towards progressive neuromuscular diseases, for which no effective treatment methods areavailable in the medical world yet. Based on the extremely high efficacy and safety results obtained in postmarket surveillance, Medical HAL Lower Limb Type was given increased points in the 2022 revision of
medical treatment fees as “a remarkable functional improvement effect unprecedented in patients with
progressive neuromuscular diseases for which no other effective treatment methods have been established,including already approved drugs” (excerpt from the medical technology evaluation proposal by the JapaneseSociety for Neurological Therapeutics).
Regarding spinal cord-related diseases, the Japanese Minister of Health, Labor, and Welfare approved
additional indications of HTLV-1-associated myelopathy (HAM) and hereditary spastic paraplegia for HAL on
October 2022. Regarding traumatic spinal cord injuries, the Company is consulting with the regulators on thenecessary steps to obtain medical device approvals.
Regarding stroke, the Company discussed the result of the investigator-initiated clinical trial using theMedical HAL Lower Limb Type single-leg model (HIT2016 trial). Considering the practice conditions
surrounding acute stroke treatment and recovery rehabilitation, the Company is preparing additional studies(clinical trials) while consulting with the regulator.
In addition, the University of Tsukuba Hospital started clinical trials to investigate the effect of HAL on
improving the physical functions of children affected by cerebral palsy in January 2022. The clinical trial iscurrently in progress. The Company has also developed a small Medical HAL Lower Limb Type model
equivalent to the device used in the clinical trial for cerebral palsy. The Company submitted paperwork to- 2 -obtain approvals from the PMDA (Pharmaceuticals and Medical Devices Agency) in June 2023 for the samegroup of patients as the larger size of Medical HAL Lower Limb Type.
(USA)

As a medical service platform for individual users, RISE Healthcare Group (RHG), the Company’s subsidiary,
is developing its business mainly in the Southern part of California. Four RHG facilities offer Cybernics
Treatment using HAL. Since January 2023, the business of RHG has gradually shifted to paid service, and thenumber of treatment sessions is increasing steadily.
The Company also obtained marketing clearance for a smaller Medical HAL Lower Limb Type model andan additional indication of cerebral palsy (above 12 years old) from the U.S. FDA in May 2024. With theapproval of the smaller model as a medical device, patients between 100 cm and 150 cm in height can now betreated with Medical HAL. In addition, the company also received approval to expand the indications for thetreatment of HTLV-1-related myelopathy (HAM) and hereditary spastic paraplegia, which were alreadyapproved in Japan.
Based on the accumulated experience of Cybernics Treatment in the U.S., the approval of a smaller modelof Medical HAL, and the expansion of approved diseases, the Company will continue to expand the businessin this region.

(EMEA: Mainly Europe and the Middle East)
The Group continues to promote Cybernics Treatment in the region. For example, following large-scaleinstallation of HAL in Türkiye, 25 units of HAL was shipped out to an Italian Social Company, Coopselios,
in May 2023. The Company is planning to ship out additional units.
In Germany, the G-BA (German Federal Joint Committee), the public health insurance authority, hasannounced that it will conduct a clinical trial for spinal cord injury based on public health insurance coverage.

Related parties are preparing for the trial.
(APAC: Asia Pacific)
CYBERDYNE MALAYSIA Sdn. Bhd. is working to disseminate Cybernics Treatment in a wide area ofSouth East Asia, India, Australia, and Taiwan.
The Group continues to strengthen its partnership with Malaysia’s government-affiliated Social Security
Organization (SOCSO) to increase access for Malaysian patients under the SOCSO coverage. In May 2024,
the Company conducted top-level meetings with the Malaysian government, including its Minister of Human
Resources at CYBERDYNE Headquarters, to disseminate Cybernics Treatment further in Malaysia. At thehigh-level meeting, the Minister expressed their intention to install 50 sets (65 units) of HAL in Malaysia'sNational Neuro-Robotics and Cybernics Rehabilitation Centre. This facility is scheduled to commence
operation at the end of year 2024.

<<Business operation around applications to support caregivers and care receivers>>
The Group has developed various types of HAL for seniors to improve their physical function, prevent illness
and frailty, and reduce the requirement for care. These include the HAL Lower Limb Type for enhancing theability to walk, the HAL Single Joint Type to train elbow, knee, and ankle movements, and the HAL Lumbar
Type to train the trunk and lower limb function.

(Service at facilities for individuals)
The Group continues to offer Neuro HALFIT, a program that induces improvement of the brain-nerve andmusculoskeletal system through utilizing HAL. The program is currently available at 18 Robocare Centers- 3 -operated by business partners. The Group plans to open additional Robocare Centers.

(Neuro HALFIT at Home as a service towards individuals)
Neuro HALFIT at Home is a home-based program where individuals rent HAL and engage in HAL-assisted
workouts at Home. The HAL Monitor, linked to Cyberdyne's cloud, visualizes bio-electrical signals thatcommand body movements and posture information and enables the wearer to obtain visual feedback. In
addition to providing online support by therapists, trainers, and other professional staff, the Company also

works with home-based service providers to promote in-person support, from setting up equipment at home to
implementing programs.
<<Prevention/early detection>>
The Group is preparing for the commercialization of the Cyvis series, an ultra-small size vital sensor designed
to manage the risk of arrhythmia and atrial fibrillation and prevent myocardial infarction, and stroke byaccumulating, analyzing, and processing various healthcare data such as cardiac activity, brain activity, bodytemperature, SpO2, and daily activities using its AI system. Cyvis also has an optional feature to measure
breathing conditions while sleeping, enabling easy yet highly accurate screening of risks of sleep apnea
syndrome. In addition, together with “JUKUSUI Alarm,” a healthcare application that visualizes sleep,developed and operated by group company C2, the Group is strengthening its healthcare business as a whole.
The Company submitted a medical device approval application for its next-generation model, Cyvis 2, on
April 2023.

<<Business operation around applications for the workplace and daily life>>(Well-being)
Since 2021, the Company has been operating the HAL Lumbar Type in nursing care facilities in Hampshire,
U.K., as a model case to spread its usage to other areas in the U.K. and other European countries.
(Labor Support, Disinfection, and Cleaning)
Regarding the next-generation Cleaning Robot CL02, which uses cutting-edge SLAM technology to achieve
high-speed autonomous driving, the Group works with major construction companies with its ability to ride onelevators automatically and connect with cloud systems; the companies are developing this technology as asolution to make building management smarter and reduce management costs. Furthermore, the company isexpanding its mobility part as a transportation robot inside the factory.
Status of Research and Development
The Group develops “Acoustic X,” a patented photoacoustic imaging system based on the LED light source
method that realizes real-time, high-resolution 3D imaging of blood vessels and blood in the peripheral organs
without needing contrast agents. The Group develops this technology as a next-generation medical image
diagnosis device. In addition, research is underway at prominent medical institutions and research facilities
around the globe to create various applications for this technology.
Furthermore, the proposal of the Group was selected for the next Cross-ministerial Strategic Innovation
Promotion Program (SIP) Third Phase: Development of Fundamental Technologies, the Establishment ofCommon Systems, Rules, and Regulations for the Expansion of Human Collaborative Robotics, Theme 6:
Development of Social Implementation Technologies for HCPS* Integrated Human Collaborative Robotics to
Solve Social Issues” that is led by the Council for Science, Technology, and Innovation (the Cabinet Office ofJapan). Under this program, the Group continues to (i) develop an application for various living spaces suchas residences, facilities, and workplaces, (ii) utilize HCPS-integrated Cybernics master remote control- 4 -technology that works together with human information (physiological, physical, behavioral, cognitive,
psychological, etc.), (iii) acquire and utilize human information obtained through non-invasive HCPSintegrated human-collaborative robotics, and (iv) Establish links with other related technologies of the R&D
theme to improve the independence and freedom of seniors and people with limited access to transportation.
At the Tonomachi International Strategic Zone (King Sky Front) in Kawasaki City, Cybernics Medical
Innovation Base Building A functions to promote the systematization of Cybernics Treatment by combining
HAL with regenerative medicine and drugs and the development of technologies that integrate medical andbio-related technologies with AI, robotics and information systems. The Company will continue coordinatingwith its C-Startup partners in regenerative medicine and drug creation.
Number of operating units
As of the end of June 2024, 481 Medical HAL Lower Limb Type units were operating worldwide, including
those used for clinical research. Ninety-six of those units were used in Japanese hospitals for treatment. In
addition, there were 634 units of HAL Single Joint Type, mainly from the increase of products for medical
use. Three hundred sixty-seven units of HAL for Well-being Lower Limb Type and HAL for Living Support
Lower Limb Type (older model) were in operation. Furthermore, 998 units of HAL Lumbar Type for Wellbeing were in operation. In addition, there were 398 units of HAL Lumbar Type for Labor Support and 175
units of Cleaning Robots and Transportation Robots.
In the consolidated three months that ended June 30, 2024, a significant increase in medical service in the US
and Europe contributed to the revenue recorded at ¥1,155 million (10.5% increase year on year). In addition,
the Group recorded a gross profit of ¥602 million (6.5% increase year on year).
The Group recorded research and development expenses at ¥205 million (a 17.7% increase year on year),mainly due to developing new products at the Company’s own cost, clinical research, and consigned research
projects. In addition, the Group recorded other selling, general, and administrative expenses at ¥681 million(11.1% decrease year on year) due to a decrease in advertising expenses and purchases of consumables.
Other income was recorded at ¥131 million (95.2% increase year on year), mainly from a consigned
research project, resulting in an operating loss of ¥153 million (50.2% decrease year on year).
The Group recorded a finance income of ¥139 million, mainly due to gains from the valuation difference ofinvestment securities and exchange gain. In addition, the Group recorded gains related to CEJ Fund at ¥22
million and income tax expense at ¥2 million from deferred tax expenses, resulting in the posting of profit

attributable to owners of the parent at ¥11 million (96.6% decrease year on year).
(2) Explanation of financial position① Assets
For the consolidated three months ended June 30, 2024, assets increased ¥115 million to ¥50,115 million
compared to the end of the previous fiscal year. Changes were mainly due to a decrease of ¥117 million
in other current assets and ¥113 million in cash and cash equivalent, partially offset by an increase of¥282 million in other financial assets (non-current) and ¥127 million in goodwill.
② Liabilities
For the consolidated three months ended June 30, 2024, liabilities increased ¥36 million to ¥9,486 million
compared to the end of the previous fiscal year. The changes were mainly due to an increase of ¥42 million
in deferred tax liabilities, partially offset by a decrease of ¥42 million in trade and other payables and ¥28
million in Lease liabilities (non-current).

- 5 -③ Equity
For the consolidated three months ended June 30, 2024, equity increased ¥152 million to ¥40,628 million
compared to the end of the previous fiscal year. Changes were mainly due to the recognition of foreign
currency translation adjustments on foreign operations.

(3) Status of cashflow
For the consolidated three months ended June 30, 2024, cash and cash equivalents decreased ¥113 million to¥5,042 million compared to the end of the previous fiscal year. The main influence factors for the cash flow

status within the consolidated three months ended June 30, 2024, are stated below.
(Cash flows from operating activities)
For the consolidated three months ended June 30, 2024, net cash provided by operating activities recorded an
inflow of ¥54 million (an outflow of ¥395 million in the previous consolidated three months). Changes weremainly due to finance income posted at ¥139 million, an increase (decrease) in trade and other payables posted
at ¥42 million, partially offset by Depreciation and amortization at ¥154 million, and a Decrease (increase) intrade and other receivables recorded at ¥117 million.

(Cash flows from investment activities)
For the consolidated three months ended June 30, 2024, net cash provided by investing activities recorded an
outflow of ¥179 million (an outflow of ¥30 million in the consolidated three months of the previous fiscal
year). The changes were mainly due to the proceeds of redemption of investments posted at ¥8,000 million,
partially offset by the purchase of investments posted at ¥8,000 million and the purchase of investment
securities posted at ¥110 million.

(Cash flows from financing activities)
For the consolidated three months ended June 30, 2024, net cash used in financing activities recorded an
outflow of ¥47 million (an inflow of ¥639 million in the consolidated three months of the previous fiscal year).

The changes were mainly due to the outflow of ¥45 million from Lease liabilities paid.

- 6 -2. Condensed quarterly consolidated financial statement(1) Condensed quarterly consolidated statement of financial position (Unaudited)
As of March 31, 2024

As of June 30, 2024

Millions of yen

Millions of yen

AssetsCurrent assets
Cash and cash equivalents
Trade and other receivables

5,155
674

5,042
557

Other financial assets

11,504

11,503Inventories

997

938

Other current assets

139

202

Total current assets

18,46918,242

Operating lease assets
Property, plant and equipment
Right of use assets
Goodwill
Intangible assets

359
13,237
482
2,134
48

342
13,216
457
2,262
47

Investments accounted for using equity method
Other financial assets

261
14,814250
15,095

Other non-current assets

196

203

Total non-current assets

31,53031,87349,99950,115

Non-current assets

Total assets- 7 -As of March 31, 2024

As of June 30, 2024

Millions of yen

Millions of yen

Liabilities and equity
Liabilities
Current liabilities
Trade and other payables
Bonds and borrowings

606
84

564
91

Lease liabilities

160

165

Other current liabilities
Total current liabilities

386

364

1,236

1,184

Non-current liabilities
Bonds and borrowings

22

21

Third-party interests in CEJ Fund
Lease liabilities

5,733
366

5,735
337

Provisions
Deferred tax liabilities

96
2,040

96
2,082

Other non-current liabilities

30

30

Total non-current liabilities

8,286

8,302

9,523

9,486

10

10

Capital surplus
Treasury shares
Other components of equity
Retained earnings

42,811(1,188)(787)(95)

42,811(1,188)(601)(84)

Total equity attributable to owners of the parent

40,75240,948Non-controlling interests
Total equity

(275)

(320)

40,477

40,628

Total liabilities and equity

49,99950,115

Total liabilities
EquityShare capital- 8 -(2) Condensed quarterly consolidated statement of profit or loss and condensed quarterly consolidated statement of comprehensive
income (Unaudited)
Condensed year to quarter end consolidated statement of profit or loss
Three months ended
June 30, 2023

Three months ended
June 30, 2024

Millions of yen
1,045

Millions of yen
1,155

Cost of sales

(480)

(553)

Gross profit

566

602

Research and development expenses
Other selling, general and administrative expenses

(174)
(766)

(205)
(681)

Total selling, general and administrative expenses
Other income

(941)
67

(887)
131

Other expenses

(1)

(0)

Finance income

(308)
369

(154)
139

Finance costs
Gains related to CEJ Fund

(6)
712

(4)
22

0

(10)

Income tax expense

767
(482)

(7)
(2)

Profit (loss)

285

(8)

Profit (loss) attributable to
Owners of parent

330

11

Non-controlling interests

(45)

(20)

Profit (loss)

285

(8)

Basic earnings (loss) per share (yen)

1.56

0.05

Diluted earnings (loss) per share (yen)

1.56

0.05

Revenue

Selling, general and administrative expenses

Operating profit (loss)

Share of profit (loss) of investments accounted for using equity
methodProfit (loss) before tax

Earnings (loss) per share- 9 -Condensed year to quarter end consolidated statement of comprehensive income

Profit (loss)

Three months ended
June 30, 2023

Three months ended
June 30, 2024

Millions of yen

Millions of yen
285

(8)

Financial assets measured at fair value through othercomprehensive income

(14)

83

Total of items that will not be reclassified to profit or loss

(14)

83

Exchange differences on translation of foreign operations

155

77

Total of items that may be reclassified to profit or loss

155

77

141

160

427

152

Owners of parent
Non-controlling interests

483
(56)

197
(45)

Comprehensive income

427

152

Other comprehensive income
Items that will not be reclassified to profit or loss

Items that may be reclassified to profit or loss

Total other comprehensive income, net of tax
Comprehensive income
Comprehensive income attributable to- 10 -

(3) Condensed quarterly consolidated statement of changes in equity (Unaudited)Three months ended June 30, 2023 (from April 1, 2023 to June 30, 2023)
Equity attributable to owners of parent
Other components of equity

Share capital

Capital surplus

Treasury shares

Millions of yen

Millions of yen

Millions of yen

Financialassetsmeasured atfair value
through othercomprehensive
incomeMillions of yen

Millions of yen

Millions of yen

10

42,877(1,188)(1,270)

272

19

－
－

－
－

－
－

－
(14)

－
166

－
－

Total comprehensive income

－

－

－

(14)

166

－

Share-based payment transactions

－

2

－

－

－

－

－

(73)

－

－

－

－

April 1, 2023
Profit (loss)
Other comprehensive income

Equity transaction with non-controllinginterest
Total transactions with owners
June 30, 2023

Exchangedifferences ontranslation offoreign
operations

Stockacquisitionrights

－

(71)

－

－

－

－

10

42,806(1,188)(1,284)438

19

Non-controllinginterests

Total equity

Equity attributable to owners of parent
Other
components ofequityRetainedearnings

Total

Millions of yen(979)

Millions of yen
1,381

Millions of yen
42,101Millions of yen(118)

Millions of yen
41,983

－
152

330
－

330
152

(45)
(11)

285
141

Total comprehensive income

152

330

483

(56)

427

Share-based payment transactions

－

－

2

－

2

－

－

(73)

31

(42)

Total
April 1, 2023
Profit (loss)
Other comprehensive income

Equity transaction with non-controllinginterest
Total transactions with owners
June 30, 2023

－

－

(71)

31

(40)

(826)

1,712

42,513(143)

42,370- 11 -

Three months ended June 30, 2024 (from April 1, 2024 to June 30, 2024)
Equity attributable to owners of parent
Other components of equity

Share capital

Capital surplus

Treasury shares

Millions of yen

Millions of yen

Millions of yen

Financialassetsmeasured atfair value
through othercomprehensive
incomeMillions of yen

Millions of yen

Millions of yen

10

42,811(1,188)(1,329)

523

19

－

－

－

－

－

－
102

－

－

－
83

Total comprehensive income

－

－

－

83

102

－

Share-based payment transactions

－

－

－

－

－

－

－

－

－

－

－

－

April 1, 2024
Profit (loss)
Other comprehensive income

Equity transaction with non-controllinginterest
Total transactions with owners
June 30, 2024

Exchangedifferences ontranslation offoreign
operations

Stockacquisitionrights

－

－

－

－

－

－

10

42,811(1,188)(1,245)625

19

Non-controllinginterests

Total equity

Equity attributable to owners of parent
Other
components ofequityRetainedearnings

Total

Millions of yen

Millions of yen

Millions of yen

Millions of yen

Millions of yen

(787)

(95)
11

40,752
11

(275)
(20)

40,477(8)

Total
April 1, 2024
Profit (loss)
Other comprehensive income

－
186

－

186

(25)

160

Total comprehensive income

186

11

197

(45)

152

Share-based payment transactions

－

－

－

－

－

－

－

－

－

－

Equity transaction with non-controllinginterest
Total transactions with owners
June 30, 2024

－

－

－

－

－

－

(601)

(84)

40,948(320)

40,628- 12 -

(4) Condensed quarterly consolidated statement of cash flows (Unaudited)

Cash flows from operating activities
Profit (loss) before tax
Depreciation and amortization

Three months ended
June 30, 2023

Three months ended
June 30, 2024

Millions of yen

Millions of yen
767
160

(7)
154

(369)
6
(712)

(139)
4
(22)

Share of loss (profit) of investments accounted for using equity
method(0)10Decrease (increase) in inventories
Decrease (increase) in trade and other receivables

(64)
(71)

59
117

Increase (decrease) in trade and other payables

(60)

(42)

Finance income
Finance costs
Loss (gains) on CEJ Fund

Other
SubtotalInterest received
Interest paid
Income tax paid

(64)

(82)

(406)

53

11
(0)

2
(0)
(1)

－

Income taxes refund

－

0

(395)

54

Cash flows from investing activities
Purchase of investments
Proceeds form redemption of investments(5,000)5,000(8,000)8,000

Purchase of property, plant and equipment

(40)

(69)

Purchase of intangible assets
Purchase of investment securities
Proceeds from sale of investment securities

(8)
(450)
465

－
(110)

Net cash provided by (used in) operating activities

Payments for loans receivable

(1)

－
－

Collection of loans receivable
Other

3
(0)

－
(0)

Net cash provided by (used in) investing activities

(30)

(179)

Cash flows from financing activities
Repayments of long-term borrowings
Repayments of lease obligation
Contributions into CEJ Fund from third-party investors
Other
Net cash provided by (used in) financing activities
Effect of exchange rate changes on cash and cash equivalents

(3)

(1)

(42)
680

(45)

4

－
(1)

639

(47)

70

58

Net increase (decrease) in cash and cash equivalents

284

(113)

Cash and cash equivalents at beginning of fiscal year

7,801

5,155

Cash and cash equivalents at end of year

8,086

5,042

- 13 -

(5) Notes to condensed quarterly consolidated financial statements(Notes on the premise of going concern)
There are no items to report.
(Segment information)(1) Service transferred over time
The Group's reportable segments are the components of the Group for which discrete financial information is available andwhich are regularly reviewed by the Board of Directors in deciding how to allocate resources and assess their performance.
Since the Group operates under a single segment of business related to robotics, segment information is omitted.
(2) Revenue and results of reportable segments
Since the Group operates under a single segment, segment information is omitted.
(3) Information about Products and Services
Please refer to the Note "Revenue" for information related to products and services.

- 14 -

(Revenue)
Disaggregation of revenue
Details of the disaggregation of revenue are set forth below.
Three months ended
June 30, 2023

Three months ended
June 30, 2024

Millions of yen

Millions of yen

Timing of revenue recognition
Service transferred over time
Asset transferred at a point of time

590
31

562
33

Service transferred at a point of time

425

560

1,045

1,155

Total

(Note) Since the Group operates under a single segment of business, segment information on revenue is omitted.
Service transferred over time
Services transferred over time include rental revenue based on individual rental contracts, maintenance revenues basedon maintenance contracts related to revenue from finance leases where the Group is a lessor of the right-of-use asset,
subscription income from the provision and operation of smartphone applications, and sponsorship income.
The Group recognizes rental revenue as revenue generated throughout the rental period after the customer accepts therelevant product using the following methods. The pay-per-use model is based on times of product usage in the relevant
month, and the base fee model is based on fixed monthly prices.
The Group recognizes maintenance revenue as a performance obligation satisfied over time. The Company records thisrevenue based on the average amount during this contract period.
The Group recognizes usage fee revenue from the provision and operation of smartphone applications as revenue overtime, as services are provided through the applications over a fixed period.
The Group recognizes sponsorship revenue by providing the right to indicate sponsorship through a title sponsorshipcontract over a fixed time.
Asset transferred at a point of time
Assets transferred at a point of time include revenues from selling commodities and products under sales contracts andrevenues related to finance leases.
The Group mainly determines that the performance obligation of sales of commodities and products is satisfied at the
point of customer acceptance of the relevant product. The Group receives most of the payment within one month fromthe point of satisfying the performance obligation. Concerning transaction price, there is no significance in the amount ofsales revenue that includes variable consideration. Furthermore, there are no significant financial components in theamount of promised consideration.
Furthermore, if the Group acts as a lessor of right-of-use of its devices, such as HAL, the Group classifies the relevant
lease as a finance lease. Finance lease income is processed in the same way as cases where the Group acts as a lessor of
manufacturer or distributor of sales of goods. The Group determines that performance obligation is satisfied at the pointof customer acceptance and the revenue is recognized at a point of time.
Service transferred at a point of time
Service transferred at a point of time includes revenue from offering Cybernics Treatment and training services at
Cybernic Treatment Center and Robocare Centers to end users (such as patients). It also includes revenue received forproviding outcomes of consigned research projects.
The Group determines that the performance obligation of Cybernics Treatment and training services is satisfied at the
point of completion of such services. The Group determines that the performance obligation of providing outcomes ofconsigned research projects is satisfied when the customer inspects and accepts the outcome.

- 15 -